- Login
- Register & Subscribe
- Langue: EN FR DE
Company News
Crucell posts strong 2009 results
Tuesday 9 February 2010
Crucell NV, the Dutch antibody and vaccine developer, produced strong results for 2009 but its fourth quarter figures suggested that it is losing some momentum.
Location
Netherlands
Novartis gets rights to hepatitis C therapy
Tuesday 9 February 2010
Novartis AG has in-licensed a new compound for the treatment of hepatitis C that is described as the first in a new class of drugs called cyclophilin inhibitors. The deal was announced on 9 February, 2010 but no financial details were disclosed.
Location
Switzerland
Oxford Nanopore funding to support DNA sequencing
Tuesday 9 February 2010
Oxford Nanopore Technologies Ltd said that it will use the proceeds of a new funding round amounting to £17.4 million to support its technology platform and in particular, its lead project in DNA sequencing.
Location
United Kingdom
Dutch company to develop diagnostic for Pfizer cancer drug
Monday 8 February 2010
The Netherlands-based diagnostics company, Qiagen NV, has reached an agreement with Pfizer Inc to develop a companion diagnostic for its immunotherapy vaccine, which is currently in Phase 2 development.
Location
Netherlands
UK cancer charity in major alliance with AstraZeneca
Sunday 7 February 2010
Cancer Research Technology (CRT) has entered into a three-year drug discovery and development alliance with AstraZeneca Plc that is expected to lead to the identification of new small molecule drugs targeting changes in a cell’s metabolism.
Location
United Kingdom
Pierre Fabre licenses cancer antibody to Abbott
Friday 5 February 2010
Privately-owed French pharmaceutical company, Pierre Fabre SA, has licensed exclusive rights to Abbott Laboratories to a preclinical monoclonal antibody for cancer that targets a membrane receptor known as c-Met.
Location
France
GSK expands restructuring despite increase in sales and profits
Thursday 4 February 2010
GlaxoSmithKline is expanding its restructuring programme in order to generate an additional, annual pre-tax savings of £500 million by 2012. Half of the savings will come from R&D where it intends to stop discovery research in depression and pain.
Location
United Kingdom
Roche’s earnings hit by Genentech acquisition
Thursday 4 February 2010
The Roche group’s net income declined by 22% to CHF 8.5 billion in 2009 as it absorbed the cost of acquiring and integrating Genentech. Group sales, however, rose by 8% and the company proposed a 20% increase in its dividend.
Location
Switzerland
Galápagos acquires contract research company
Wednesday 3 February 2010
Galápagos NV, which performs discovery research for itself and for other companies using a functional genomics platform, has acquired Argenta Discovery Ltd, a privately-held contract research organization, for €16.5 million in cash.
Location
Belgium
Cytos concentrates on partnerships to conserve cash
Wednesday 3 February 2010
Cytos Biotechnology AG, the Swiss developer of therapeutic vaccines, is focusing its future development work on partnerships with Novartis and Pfizer to conserve cash ahead of the scheduled repayment of its convertible debt in February 2012.
Location
Switzerland
Select a News Category
Recent Appointments
Pascale Witz to head strategic development at Sanofi
Monday May 6 2013
Srinivas Akkaraju joins Sofinnova Ventures
Monday May 6 2013
Vicente Anido nominated to Nicox board
Monday May 6 2013
Jeremy Farrar named director of the Wellcome Trust
Monday May 6 2013
Harry Kirsch becomes CFO at Novartis
Monday May 6 2013